These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2764127)

  • 1. Calf sweat lactate in peripheral arterial occlusive disease.
    Fellmann N; Fabry R; Coudert J
    Am J Physiol; 1989 Aug; 257(2 Pt 2):H395-8. PubMed ID: 2764127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Transcutaneous measures of oxygen partial pressure and capillaroscopic parameters as affected by naftidrofuryl in patients with obliterative arteriopathies, Fontaine stages II-IV].
    Ranft J; Heidrich H; Lammersen T
    J Mal Vasc; 1987; 12(1):78-81. PubMed ID: 3559415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. tcpO2, arterial blood flow and lactate/pyruvate modifications induced by a single dose of naftidrofuryl IV during stage III lower-limb arteriopathies.
    Pointel JP; Thomas C; Mosnier M; Percebois G; Debry G
    Angiology; 1986 Sep; 37(9):647-53. PubMed ID: 3767072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naftidrofuryl in chronic arterial disease. Results of a controlled multicenter study.
    Trübestein G; Böhme H; Heidrich H; Heinrich F; Hirche H; Maass U; Mörl H; Rudofsky G
    Angiology; 1984 Nov; 35(11):701-8. PubMed ID: 6388425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of naftidrofuryl on transcutaneous oxygen tension during a treadmill test in patients with peripheral arterial occlusive disease.
    Mouren X; Caillard P; Bensoussan JJ; Massonneau M; Gamand S; Stevens WH
    Vasc Med; 1998; 3(1):9-14. PubMed ID: 9666526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A metabolic approach to the evaluation of peripheral vascular disease.
    O'Donnel TF; Clowes GH; Browse NL; Ryan NT; Blackburn GL
    Surg Gynecol Obstet; 1977 Jan; 144(1):51-7. PubMed ID: 12579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of the analgesic effect of naftidrofuryl in permanent ischemia in patients with arterial diseases. Double-blind versus placebo study].
    Testart J; Guidicelli H; Glanddier G; Mosnier M
    Ann Cardiol Angeiol (Paris); 1994 Nov; 43(9):542-7. PubMed ID: 7864561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Double-blind study of naftidrofuryl-hydrogen oxalate in peripheral arterial occlusive disease].
    Pohle W; Hirche H; Barmeyer J; Schümichen C; Hoffmann G
    Med Welt; 1979 Feb; 30(7):269-72. PubMed ID: 372733
    [No Abstract]   [Full Text] [Related]  

  • 9. [Naftidrofuryl in arterial occlusive disease. Controlled multicenter double-blind study with oral administration].
    Maass U; Amberger HG; Böhme H; Diehm C; Dimroth H; Heidrich H; Heinrich F; Hirche H; Mörl H; Müller-Bühl U
    Dtsch Med Wochenschr; 1984 May; 109(19):745-50. PubMed ID: 6373217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of intravenous naftidrofuryl on the microcirculation of patients in stages III and IV of arterial occlusive disease].
    Abendroth D; Sunder-Plassmann L
    Vasa Suppl; 1988; 24():33-7. PubMed ID: 3212601
    [No Abstract]   [Full Text] [Related]  

  • 11. Intra-arterial prostacyclin compared to Praxilene in the management of severe lower limb ischaemia: a double blind trial.
    Negus D; Irving JD; Friedgood A
    J Cardiovasc Surg (Torino); 1987; 28(2):196-9. PubMed ID: 2435738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Studies on tissue PO2 and biochemical analysis of the skeletal muscle of legs with chronic arterial occlusive diseases].
    Yamamoto T; Fujiwara T; Dokoh S; Inada H; Masaki H; Katsumura T; Ichihara K
    Nihon Geka Gakkai Zasshi; 1988 May; 89(5):771-5. PubMed ID: 3412309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intravenous infusion of Naftidrofuryl in the treatment of arterial diseases of the limbs. Clinical and functional study].
    Schmidt C; Royer RJ; Kissel P
    Therapie; 1974; 29(6):915-23. PubMed ID: 4618388
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease.
    Barradell LB; Brogden RN
    Drugs Aging; 1996 Apr; 8(4):299-322. PubMed ID: 8920176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical changes in sweat following prolonged ischemia.
    Ferguson-Pell M; Hagisawa S
    J Rehabil Res Dev; 1988; 25(3):57-62. PubMed ID: 3411526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of naftidrofuryl on creatinine serum concentration and on PAH/inulin clearance in peripheral arterial occlusive diseases].
    Heidrich VH; Baethke R; Beyer KH
    Arzneimittelforschung; 1975 Mar; 25(3):429-31. PubMed ID: 1174049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oxygen pressure values in the ischemic muscle tissue of patients with occlusive arterial diseases (author's transl)].
    Ehrly AM; Köhler HJ; Schroeder W; Müller R
    Klin Wochenschr; 1975 Jul; 53(14):687-8. PubMed ID: 1219182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some haemorheological factors and transcutaneous PO2 in patients with a peripheral arterial occlusive disease after treatment with naftidrofuryl.
    Krupiński K; Bielawiec M; Szpak A; Płonowski A
    Mater Med Pol; 1994; 26(1):17-20. PubMed ID: 7857406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Capillary microscopic effect of naftidrofuryl in peripheral arterial occlusive disease].
    Heidrich H; Ranft J
    Vasa Suppl; 1988; 24():17-20. PubMed ID: 3212599
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of oxygen inhalation and intravenous naftidrofuryl on the transcutaneous partial oxygen pressure in ischaemic lower limbs.
    Mustapha NM; Jain SK; Dudley P; Redhead RG
    Prosthet Orthot Int; 1984 Dec; 8(3):135-8. PubMed ID: 6522254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.